There are diverting reports on the prognostic value of PSMA PET derived total tumor volume in patients with end-stage prostate cancer who receive Lu-PSMA therapy: Ferdinandus et al. could show that the FDG PET derived total tumor volume and the bone scan derived tumor volume were negative prognosticators of survival; yet the PSMA PET derived tumor volume was not a statistically significant prognosticator in their study [12]. The gene discussed is FOLH1; the disease is neoplasm.